

Article

# Molecular Investigation of Carbapenems KPC and NDM Genes Among *Klebsiella Pneumoniae* Strains Isolated from Various Clinical Samples in Al-Basrah Province, Iraq

Duha Hassan Abdul-Wahab<sup>1</sup>, Saad Shakir Mahdi Al-Amara<sup>2\*</sup>, Talib Abdulmaged Alboslemy<sup>3</sup>

1. M.Sc. Student, Department of Biology, College of Science, University of Basrah, Iraq
2. Department of Pathological analyses, College of Science, University of Basrah, Iraq
- \* Correspondence: [saad.mahdi@uobasrah.edu.iq](mailto:saad.mahdi@uobasrah.edu.iq)
3. Department of Biology, College of Science, University of Basrah, Iraq

**Abstract:** Carbapenem is the final defense against Gram-negative ESBLs producing antibiotics, with resistance to Enterobacteriaceae, particularly Carbapenem-resistant *Klebsiella pneumoniae* (CR-KP), posing a significant public health threat. The samples for the current investigation were from three hospitals in the Iraqi, region of Al-Basrah. The n = 26 *K. pneumoniae* isolates were previously collected by the master's study between October 2022 and December 2022. The *K. pneumoniae* isolates were reactivated and reidentified using a PCR technique using the diagnostic gene 16S rDNA. The isolates were then grown on MacConkey agar, *K.pneumoniae* chromogenic media and confirm identified by PCR technique by using specific primer for *K.pneumoniae* had a molecular weight of approximately 130 bp. The results showed that all n= 26 isolates are (100%) *K. pneumoniae*. Modified Hodge Test (MHT) was performed on all n=26 *K. pneumoniae* isolates. The results in the current study showed that out of n=26 *K.pneumoniae* isolates the 19(73%) isolates gave positive results for production of carbapenemase. While the 7(26.923%) isolates were showed negative results for produced carbapenemase. Carbapenemase genes was detected by using two specific primers *bla<sub>KPC</sub>* and *bla<sub>NDM</sub>* genes. The amplified genes' bands were characterized approximately at (480 bp) and (621) respectively, compared to the stander molecular DNA ladder at (2000 bp), results were shown the all n=26 *K. pneumoniae* isolates had gave negative results for the *bla<sub>KPC</sub>* gene. On the other hand, only 17(65.384%) *K.pneumoniae* isolates were gave positive results for detection of *bla<sub>NDM</sub>* gene. While 9(34.615%) *K.pneumoniae* isolates were gave negative results for detection the *bla<sub>NDM</sub>* gene.

**Keywords:** *Klebsiella pneumoniae*, carbapenemase, *bla<sub>KPC</sub>* and *bla<sub>NDM</sub>* genes

**Citation:** Abdul-Wahab, D. H., Al-Amara, S. S. M., & Alboslemy, T. A. Molecular Investigation of Carbapenems KPC and NDM Genes Among *Klebsiella Pneumoniae* Strains Isolated from Various Clinical Samples in Al-Basrah Province, Iraq. Central Asian Journal of Medical and Natural Science 2024, 5(4), 24-29.

Received: 24<sup>th</sup> Jun 2024

Revised: 1<sup>st</sup> Jul 2024

Accepted: 8<sup>th</sup> Jul 2024

Published: 15<sup>th</sup> Jul 2024



**Copyright:** © 2024 by the authors. Submitted for open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>)

## 1. Introduction

The final line of defense against Gram-negative extended spectrum  $\beta$ -lactamases (ESBLs) producing antibiotics is carbapenem [1,2]. Resistance to carbapenems Enterobacteriaceae, in particular Carbapenem-resistant *Klebsiella pneumoniae* (CR-KP), are known to pose a significant threat to public health [3,4]. In 1996, *K. pneumoniae* carbapenemase was initially identified in the United States and subsequently dispersed throughout [5]. Carbapenemases are  $\beta$ -lactamases that hydrolyze penicillins, usually cephalosporins and carbapenems at different levels and monobactams except metallo- $\beta$ -lactamases (MBL) [6]. The most commonly reported carbapenemases are class A (serine carbapenemases, such as *K. pneumoniae* carbapenemase (KPC), class B (MBLs, such as New Delhi MBL (NDM), Verona integron-encoded MBL (VIM), and imipenemase (IMP), and class D (OXA carbapenemase such as *bla<sub>OXA-48</sub>* [7, 8]. However, the increasing use of carbapenems has resulted in the

emergence of carbapenem-hydrolyzing  $\beta$ -lactamases (carbapenemases) as a common mechanism of resistance to carbapenem agents [9].

When treating serious infections caused by multidrug-resistant Gram-negative bacteria, such as *K. pneumoniae*, carbapenems are a dependable and efficient  $\beta$ -lactam antibiotic that are often used as a last resort [5]. Three pathways mediated carbapenem resistance in *K. pneumoniae*. First, there is the generation of carbapenemases; second, there is an outer membrane porin mutation coupled with an increase in AmpC  $\beta$ -lactamase synthesis; and third, there is the extended-spectrum drug efflux or porin mutation-induced  $\beta$ -lactamase (ESBL) synthesis. The most often mentioned resistance mechanism is carbapenemase synthesis [10]. This study aimed to detect *bla<sub>KPC</sub>* and *bla<sub>NDM</sub>* genes in carbapenem-resistant *K. pneumoniae* isolates from different clinical samples from the Al-Basrah province, Iraq.

## 2. Materials and Methods

### Collection of Samples

The investigation were included n=26 *K. pneumoniae* isolates previously isolated during a master's study from three local hospitals in Al-Basrah, province, Iraq. The samples had been collected between October 2022 and December 2022 from urine, sputum, and wound swab samples from patients with UTIs, chest infections, and other illnesses. *K. pneumoniae* isolates were reactivated and re-identified according to [11,12] and kept in refrigerated until used in other tests.

### Detection of Carbapenemase Producing Isolates

#### *Klebsiella pneumoniae* chromogenic medium

According to the manufacturer's instructions, the *K. pneumoniae* isolates were tested for the capacity to produce carbapenemase using the KPC chromogenic agar.

### Modified Hodge Test (MHT)

According to CLSI, [13] the MHT test was performed on all n=26 *K. pneumoniae* isolates.

### DNA Extraction

Using the Presto™ Mining DNA Bacteria, Geneaid, USA, kit procedure, for extracted genomic DNA from n=26 *K. pneumoniae* isolates.

### Detection of 16S rDNA


The 16S rDNA amplification of the *K. pneumoniae* isolate DNA was carried out by PCR using a specific primer that had a length approximately 130 bp [14, 15]. standard molecular DNA ladder (2000 bp) was used compare the PCR results.

### Detection of carbapenemase Genes


Two different specific primers that were utilized for amplified *bla<sub>KPC</sub>* and *bla<sub>NDM</sub>* genes by PCR with a particular primer that was approximately (480 bp) and (621 bp) in length respectively according to [16].

## 3. Results

The study examined n=26 *K. pneumoniae* isolates on MacConkey agar and *K. pneumoniae* chromogenic media, the results revealing mucoid pink, white, and purple colonies respectively Figure 1. PCR-based molecular diagnostics revealed a molecular weight of approximately 130 bp for all n=26 *K. pneumoniae* isolates, based on the 16S rDNA diagnostic gene as in Figure 2.




**Figure 1.** The *Klebsiella pneumoniae* (A) on MacConkey agar, (B) on *K. pneumoniae* chromogenic media



**Figure 2.** PCR Amplified Products of 16S rDNA. Lane 1:(2000 bp DNA ladder), Lane:( no. 2-11) 16S rDNA band of *K. pneumoniae* isolates using 1.5% agarose gel, 70V, 45min

The results in the current study showed that out of  $n=26$  *K.pneumoniae* isolates the 19 (73%) isolates gave positive results for production of carbapenemase, while the 7 (26.923%) isolates were showed negative results for produced carbapenemase by using the modified hodge test (MHT). PCR was used to amplify the *bla<sub>KPC</sub>* and *bla<sub>NDM</sub>* genes. The amplified genes' bands were characterized approximately at (480 bp) and (621) respectively, compared to the stander molecular DNA ladder at (2000 bp), results were shown the all  $n=26$  *K. pneumoniae* isolates had gave negative results for the *bla<sub>KPC</sub>* gene. On the other hand, the results of the current study showed that only 17(65.384%) *K.pneumoniae* isolates were gave positive results for detection of *bla<sub>NDM</sub>* gene. While 9(34.615%) *K.pneumoniae* isolates were gave negative results for detection the *bla<sub>NDM</sub>* gene by using PCR technique as in Figure 3.



**Figure 3.** PCR Amplified Products of *bla<sub>NDM</sub>*. Lane 1:(2000 bp DNA ladder), Lane:( no. 2-16) *bla<sub>NDM</sub>* band of *K. pneumoniae* isolates . using 1.5% agarose gel, 70V, 45min

#### 4. Discussion

The n=26 *K. pneumoniae* isolates previously isolated during a master's study between October 2022 and December 2022 were reactivated by using brain-heart infusion broth and confirm identification through used MacConkey agar and *K. pneumoniae* chromogenic media. Lactose fermentation produced big, mucosal colonies on MacConkey agar, as lactose ferments, lactic acid is produced, while *K. pneumoniae* chromogenic media produced purple colonies [12]. Comparing this study to earlier research carried out in Erbil (95.45%) [17], Hilla hospitals (22%) [18], Iran (25%) [19], and Saudi Arabia hospitals (14.7%) [20], the prevalence rate of *K. pneumoniae* isolates is lower. The rate of *K. pneumoniae* isolation in China has increased and a high in 2020. The study found that the most prevalent organism in 13 (26%), sputum in 11 (22%), and wound swabs in 8 (16%) of the urine samples was *K. pneumoniae* infection [21]. Previous studies have demonstrated that 18 (36%) of the cases of *K. pneumoniae* were isolated from sputum, 16 (32%) from blood, 9 (8%), from urine, and 7 (14%), from wound swabs. This is not the case anymore. *K. pneumoniae* is the second most common cause of UTIs associated with medical treatment [22].

On the other hand, in agreement with research conducted in Baghdad (20%), *K. pneumoniae* isolates have likewise demonstrated the greatest prevalence in urine sample frequency.[21] Egypt (50%), Duhok City (66.2%), and which accounts for 11(22%) of the isolates in the current investigation from sputum, is a frequent cause of hospital-acquired pneumonia. It is linked to ventilator-associated pneumoniae and a causal agent in severe infections such as surgical wound infections and septicemia. Hospital-acquired pneumonia is caused by the colonization of mucosal surfaces by *K. pneumoniae* [23]. Following the transmission of infections and detecting *K. pneumoniae* cases depend heavily on genotyping. Because genotypic characterization techniques may be adjusted to growth conditions, temperature, and environmental variables, they are more precise. Because it has a gene, 28 16S rDNA diagnosis is better than biochemical and phenotypic approaches [24,25]. For epidemiological purposes, the Modified Hodge test (MHT), which used for detects carbapenemases, might be a highly useful screening test for identifying those kinds of infections [26,27]. The CLSI suggests the MHT test as a method of identifying the synthesis of carbapenemase [26,28&29]. Out of n=26 *K. pneumoniae* isolates, 19(73%) isolates gave positive results for production of carbapenemase. While the 7(26.923%) isolates were showed negative results for produced carbapenemase. Study of [3] indicates that (52.17%) of *K. pneumoniae* isolates gave a positive result for MHT. Also the study of [31] the results were showed that out of 32 *K. pneumoniae* isolates, 16 (50%) showed positive results and 16 (50%) showed negative results for carbapenemase production. While the just 17% and 24% of isolates from study of [26] and [32] which produce positive results respectively. The results of MHT methods in current study, was confirm by diagnosis the *K. pneumoniae* isolates that produced carbapenemase depends on PCR, through used the specific primers for the *bla<sub>KPC</sub>* and *bla<sub>NDM</sub>* genes. The results showed all n=26 *K. pneumoniae* isolates gave the negative results for *bla<sub>KPC</sub>* genes. On other hand the results of the current study showed that only 17(65.384%) *K.pneumoniae* isolates were gave positive results for detection of *bla<sub>NDM</sub>* gene. While 9(34.615%) *K.pneumoniae* isolates were gave negative results for detection the *bla<sub>NDM</sub>* gene by using PCR technique. The study of [31] reported depending on the diagnostic the *bla<sub>NDM</sub>* gene showed that all (n=32) *K. pneumoniae* isolates revealed (100%) to *bla<sub>NDM</sub>* gene. The study of [33] refer to The two most significant enzymes among the well known varieties of carbapenemases are *bla<sub>KPC</sub>* and *bla<sub>NDM</sub>*. As well, *bla<sub>NDM</sub>* gene expression was common in *K. pneumoniae* strains resistant to carbapenem, whereas *bla<sub>KPC</sub>* gene expression was absent from all *K. pneumoniae* isolates.

#### 5. Conclusion

*Klebsiella pneumoniae* that is resistant to carbapenems is a significant hazard to public health. In local laboratories and hospitals, the Modified Hodge Test (MHT) is helpful in determining the production of carbapenemase. To identify carbapenem-resistant *Klebsiella*

*pneumoniae* and its possible horizontal gene transfer, correlations between antibiotic resistance profiles and carbapenem-resistant gene PCR patterns are essential to detect the carbapenems resistance isolates.

## 6. Acknowledgements

The Department of Biology, College of Science, University of Basrah, Iraq, provided support for the study.

## REFERENCES

- [1] J. D. Pitout and K. B. Laupland, "Extended-Spectrum  $\beta$ -Lactamase-Producing Enterobacteriaceae: An Emerging Public-Health Concern," *Lancet Infect. Dis.*, vol. 8, pp. 159-166, 2008.
- [2] A. Amjad, I. A. Mirza, S. A. Abbasi, U. Farwa, N. Malik, and F. Zia, "Modified Hodge Test: A Simple and Effective Test for Detection of Carbapenemase Production," *Iran J. Microbiol.*, vol. 3, p. 189, 2011.
- [3] K. E. Holt, H. Wertheim, R. N. Zadoks, S. Baker, C. A. Whitehouse, D. Dance, et al., "Genomic Analysis of Diversity, Population Structure, Virulence, and Antimicrobial Resistance in *Klebsiella pneumoniae*, an Urgent Threat to Public Health," *Proc. Natl. Acad. Sci.*, vol. 112, pp. E3574-E3581, 2015.
- [4] H. Arabaghian, T. Salloum, S. Alousi, B. Panossian, G. F. Araj, and S. Tokajian, "Molecular Characterization of Carbapenem Resistant *Klebsiella pneumoniae* and *Klebsiella quasipneumoniae* Isolated from Lebanon," *Sci. Rep.*, vol. 9, pp. 1-12, 2019.
- [5] H. H. Mohammed, A. T. Saadi, and N. A. Yaseen, "Detection of Carbapenem Antibiotic Resistance in *Klebsiella pneumoniae* in Duhok City, Kurdistan Region, Iraq," *Duhok Med. J.*, vol. 14, no. 1, pp. 28-43, 2020.
- [6] L. S. Tzouveleakis, A. Markogiannakis, M. Psychogiou, P. T. Tassios, and G. L. Daikos, "Carbapenemases in *Klebsiella pneumoniae* and Other Enterobacteriaceae: An Evolving Crisis of Global Dimensions," *Clin. Microbiol. Rev.*, vol. 25, pp. 682-707, 2012.
- [7] T. Y. Yang, Y. J. Hsieh, L. T. Kao, et al., "In Vitro and In Vivo Evaluations of  $\beta$ -Lactam/ $\beta$ -Lactamase Mono- and Combined Therapies Against Carbapenem-Nonsusceptible Enterobacteriaceae in Taiwan," *Microorganisms*, vol. 8, p. 1981, 2020.
- [8] N. Gupta, B. M. Limbago, J. B. Patel, and A. J. Kallen, "Carbapenem-Resistant Enterobacteriaceae: Epidemiology and Prevention," *Clin. Infect. Dis.*, vol. 53, no. 1, pp. 60-67, 2011.
- [9] R. Canton, M. Akova, Y. Carmeli, C. G. Giske, Y. Glupczynski, M. Gniadkowski, et al., "Rapid Evolution and Spread of Carbapenemases Among Enterobacteriaceae in Europe," *Clin. Microbiol. Infect.*, vol. 18, no. 5, pp. 413-431, 2012.
- [10] A. Shibl, M. Al-Agamy, Z. Memish, and A. Senok, "The Emergence of OXA-48- and NDM-1-Positive *Klebsiella pneumoniae* in Riyadh, Saudi Arabia," *Int. J. Infect. Dis.*, vol. 17, 2013.
- [11] J. J. Holt, N. R. Krieg, B. H. A. Sneath, J. T. Staley, and S. T. Williams, *Bergey's Manual Determinative Bacteriology*, 9th ed. Baltimore: Williams and Wilken, 1994, pp. 175-248.
- [12] J. P. Harley and L. M. Prescott, *Laboratory Exercises in Microbiology*, 5th ed. New York: The McGraw-Hill Companies, Inc., 2002.
- [13] Clinical and Laboratory Standards Institute (CLSI), *Performance Standards for Laboratory Antimicrobial Testing*, 30th ed., Wayne, Pennsylvania, USA, 2020.
- [14] R. Podschun and U. Ullmann, "*Klebsiella* spp. as Nosocomial Pathogens: Epidemiology, Taxonomy, Typing Methods, and Pathogenicity Factors," *Clin. Microbiol. Rev.*, vol. 11, no. 4, pp. 589-603, 1998.
- [15] K. M. Osman, H. M. Hassan, A. Orabi, and A. S. Abdelhafez, "Phenotypic, Antimicrobial Susceptibility Profile and Virulence Factors of *Klebsiella pneumoniae* Isolated from Buffalo and Cow Mastitic Milk," *Pathog. Glob. Health*, vol. 108, no. 4, pp. 191-199, 2014.
- [16] M. F. Mushi, S. E. Mshana, C. Imirzalioglu, and F. Bwanga, "Carbapenemase Genes Among Multidrug Resistant Gram-Negative Clinical Isolates from a Tertiary Hospital in Mwanza, Tanzania," *BioMed Res. Int.*, 2014.
- [17] F. A. Ali and R. M. Ismael, "Dissemination of *Klebsiella pneumoniae* and *Klebsiella oxytoca* Harboring bla TEM Genes Isolated from Different Clinical Samples in Erbil City," *Diyala J. Med.*, vol. 12, no. 2, pp. 40-51, 2017.
- [18] F. M. Abbas and E. M. Jarallah, "Detection of OXA-23 Among Carbapenem Resistant Clinical Isolates of *Klebsiella pneumoniae* in Hilla," *J. Babylon Univ. Pure Appl. Sci.*, vol. 2, no. 25, pp. 435-440, 2017.

- [19] D. Mansury, M. Motamedifar, J. Sarvari, B. Shirazi, and A. Khaledi, "Antibiotic Susceptibility Pattern and Identification of Extended Spectrum  $\beta$ -Lactamases (ESBLs) in Clinical Isolates of *Klebsiella pneumoniae* from Shiraz, Iran," *Iran J. Microbiol.*, vol. 8, no. 1, pp. 55-61, 2016.
- [20] N. A. Jalal, A. M. Al-Ghamdi, A. M. Momenah, S. S. Ashgar, F. Bantun, F. S. Bahwerth, and H. Faidah, "Prevalence and Antibiogram Pattern of *Klebsiella pneumoniae* in a Tertiary Care Hospital in Makkah, Saudi Arabia: An 11-Year Experience," *Antibiotics*, vol. 12, no. 1, p. 164, 2023.
- [21] A. M. A. Al-Musawi, "Genotypic and Phenotypic Typing of Clinical *Klebsiella pneumoniae* Local Isolates," M.Sc. Thesis, College of Science, Al-Mustansiriyah University, 2018.
- [22] C. Caneiras, L. Lito, J. Melo-Cristino, and A. Duarte, "Community- and Hospital-Acquired *Klebsiella pneumoniae* Urinary Tract Infections in Portugal: Virulence and Antibiotic Resistance," *Microorganisms*, vol. 7, no. 5, p. 138, 2019.
- [23] F. Cheng, Z. Li, S. Lan, W. Liu, X. Li, Z. Zhou, Z. Song, J. Wu, M. Zhang, and W. Shan, "Characterization of *Klebsiella pneumoniae* Associated with Cattle Infections in Southwest China Using Multi-Locus Sequence Typing (MLST), Antibiotic Resistance and Virulence Associated Gene Profile Analysis," *Braz. J. Microbiol.*, vol. 49, no. 1, pp. 93-100, 2018.
- [24] J. E. Clarridge, "Impact of 16S rDNA Gene Sequence Analysis for Identification of Bacteria on Clinical Microbiology and Infectious Diseases," *Clin. Microbiol. Rev.*, vol. 17, no. 4, pp. 840-862, 2004.
- [25] T. H. Gadban, S. S. Al-Amara, and H. A. Jasim, "16S rRNA Profiling of Nine Global New Strains of *Staphylococcus aureus* Isolated from Clinical Specimens in Basrah Province, Iraq," *J. Popul. Ther. Clin. Pharmacol.*, vol. 30, no. 3, pp. 232-239, 2022.
- [26] A. Anjad, I. A. Mirza, S. A. Abbasi, U. Farwa, N. Malik, and F. Zia, "Modified Hodge Test: A Simple and Effective Test for Detection of Carbapenemase Production," *Iran. J. Microbiol.*, vol. 3, no. 4, p. 189, 2011.
- [27] A. A. Albadery, S. S. Al-Amara, and A. A. Al-Abdullah, "Phenotyping and Genotyping Evaluation of *E. coli* Produces Carbapenemase Isolated from Cancer Patients in Al-Basrah, Iraq," *Arch. Razi Inst.*, vol. 78, no. 3, pp. 823-829, 2023.
- [28] M. J. Hardany, A. A. Al-Abdullah, S. S. Al-Amara, and H. M. Makki, "Molecular Investigation of Gram Negative Bacteria Extended Spectrum  $\beta$ -Lactamase in Haemodialysis Patients in Basrah Province, Iraq," *Plant Arch.*, vol. 20, pp. 1573-1576, 2020.
- [29] J. B. Patel and F. R. JA, "Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fourth Informational Supplement," *M100-S24*, 2014.
- [30] M. A. Khalil, A. Elgaml, and M. El-Mowafy, "Emergence of Multidrug-Resistant New Delhi Metallo- $\beta$ -Lactamase-1-Producing *Klebsiella pneumoniae* in Egypt," *Microb. Drug Resist.*, vol. 23, no. 4, pp. 480-487, 2017.
- [31] I. M. Mozan and S. S. Al-Amara, "Frequencies New Delhi Metallo- $\beta$ -Lactamase (NDM) in *Klebsiella pneumoniae* Isolates from Clinical Samples in Al-Basrah Governorate, Iraq," *Sci. J. Med. Res.*, vol. 7, no. 27, pp. 15-18, 2023.
- [32] R. Aseem, S. Shenoy, S. S. Mala, S. Baliga, and A. Ashish, "Approach to Carbapenemase Detection in *Klebsiella pneumoniae* in Routine Diagnostic Laboratories," *J. Clin. Diagn. Res.*, vol. 10, no. 12, pp. DC24-DC26, 2016.
- [33] S. Indrajith et al., "Molecular Insights of Carbapenem Resistance *Klebsiella pneumoniae* Isolates with Focus on Multidrug Resistance from Clinical Samples," *J. Infect. Public Health*, vol. 14, pp. 131-138, 2021.